Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease. The Company is developing KRX-0401, an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, and also affects a number of other key signal transduction pathways, including the Jun N-terminal kinases pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and survival. KRX-0401 is in Phase III clinical development for both refractory advanced colorectal cancer and relapsed / refractory multiple myeloma, and in Phase I and Phase II clinical development for other tumor types. It is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes.

Aegerion Pharmaceuticals, Inc. (Aegerio) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders. As of December 31, 2011, the Company developed its first product candidate, lomitapide, as an oral, once-a-day treatment for patients with a inherited lipid disorder called homozygous familial hypercholesterolemia (HoFH). The Company conducted a 78-week Phase III clinical trial of lomitapide in the treatment of adult patients with HoFH. The 56-week results of the trial were announced in May 2011. It completed the trial during the year ended December 31, 2011, and in January 2012, announced the 78-week results of the trial, which were consistent with the 56-week results. In 2011, the United States Food and Drug Administration (FDA) granted orphan drug designation for lomitapide in the treatment of HoFH.

Omthera Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of new therapies for abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular disease. Epanova, its product candidate, is a late-stage, omega-three free fatty acid composition that reduces triglycerides, improves other key lipid parameters. Epanova is a coated soft gelatin capsule containing a complex mixture of polyunsaturated free fatty acids derived from fish oils, including multiple long-chain omega-three and omega-six fatty acids, with eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid being the most abundant forms of omega-three fatty acids. The Company has completed pharmacokinetic and Phase III clinical studies to investigate the safety and efficacy profile of Epanova.

MannKind Corporation (MannKind) is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. The Company s product candidate, AFREZZA (insulin human) inhalation powder, is insulin that is in late-stage clinical investigation for the treatment of adults with type I or type II diabetes for the control of hyperglycemia. The AFREZZA inhalation powder is centered on a class of potential of hydrogen (pH)-sensitive organic molecules. AFREZZA utilizes its Technosphere formulation technology. As of December 31, 2011, MannKind had not generated any product revenues. As of December 31, 2011, the AFREZZA clinical program had involved 61 different studies of AFREZZA and over 5,600 adult patients.

Amicus Therapeutics, Inc. (Amicus) is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration. It is focused on the development of pharmacological chaperone monotherapy programs and pharmacological chaperones in combination with enzyme replacement therapy (ERT). Its approach to the treatment of human genetic diseases consists of using pharmacological chaperones that selectively bind to the target protein. Amicus is also conducting preclinical studies on the use of its pharmacological chaperone technology to treat Parkinson s disease, with an initial focus on Parkinson s disease patients who are also Gaucher disease carriers.

Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. Ampyra (dalfampridine) is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP). It also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug for the management of spasticity. Ampyra is marketed as Fampyra outside the United States by Biogen Idec International GmbH (Biogen Idec). On February 6, 2012, the Company launched tizanidine hydrochloride capsules, an authorized generic version of Zanaflex Capsules under an agreement with Watson Pharma, Inc. In December 2012, the Company acquired Neuronex, Inc.

TESARO, Inc. (TESARO) is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company s marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). TSR-011 is an orally available anaplastic lymphoma kinase (ALK), inhibitor (targeted anti-cancer agent) is in preclinical development.

BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for serious diseases and medical conditions. As of December 31, 2011, its product portfolio includes four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). As of December 31, 2011, BioMarin conducted clinical trials on a number of investigational product candidates for the treatment of various diseases, including GALNS; PEG-PAL, an enzyme substitution therapy for the treatment of phenylketonuria (PKU); BMN-701, an enzyme replacement therapy; BMN-673, an orally available poly (ADP-ribose) polymerase, or PARP inhibitor for the treatment of patients with certain cancers, and BMN-111, a peptide therapeutic for the treatment of achondroplasia. In January 2013, the Company acquired Zacharon Pharmaceuticals.

Theravance, Inc. (Theravance) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas, including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company s key programs include: RELOVAIR, LAMA/LABA (719/vilanterol (VI)) and Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA), each partnered with GlaxoSmithKline plc (GSK), and its oral Peripheral Mu Opioid Receptor Antagonist program. Its drug discovery efforts are based on the principles of multivalency. Multivalency involves the simultaneous attachment of a single molecule to multiple binding sites on one or more biological targets.